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Introduction {#sec005}
============

Schizophrenia is one of the leading causes of disability within mental illnesses worldwide, and the debilitating disease results in a large impact on individuals and society \[[@pone.0234121.ref001]\]. Individuals with schizophrenia have lower life expectancy, and reduced quality of life \[[@pone.0234121.ref002], [@pone.0234121.ref003]\]. Furthermore, their relatives and caregivers also report significant impacts on daily activities \[[@pone.0234121.ref002]\]. Some patients diagnosed with schizophrenia only experience minimal to no symptomatic response from antipsychotic treatment and have so called treatment-resistant schizophrenia (TRS) \[[@pone.0234121.ref004]--[@pone.0234121.ref008]\]. The only approved pharmacotherapy for TRS is clozapine, but its use is restricted by serious adverse events and the required monitoring for patients undergoing clozapine treatment \[[@pone.0234121.ref004], [@pone.0234121.ref009], [@pone.0234121.ref010]\]. Additionally, half of patients with TRS are intolerant or resistant to clozapine \[[@pone.0234121.ref011]\].

The definition of treatment resistance is reported inconsistently across studies, and there is currently no International Statistical Classification of Diseases and Related Health Problems (ICD) code for TRS, nor does Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 include a diagnostic code \[[@pone.0234121.ref012], [@pone.0234121.ref013]\]. Treatment-resistant schizophrenia is clinically defined as *a condition whereby a person with schizophrenia symptomatology has no or minimal clinical improvement following ≥2 dopamine D*~*2*~*-preferring antipsychotics of adequate dose and duration*, *as assessed by a practicing clinician* \[[@pone.0234121.ref004], [@pone.0234121.ref014], [@pone.0234121.ref015]\].

It is described that up to 30% of all people with schizophrenia will at some point experience treatment resistance \[[@pone.0234121.ref007], [@pone.0234121.ref016]\], although numbers vary significantly in the literature, where rates of 10--60% have been reported \[[@pone.0234121.ref004], [@pone.0234121.ref007], [@pone.0234121.ref016]--[@pone.0234121.ref020]\]. In a Danish setting, using three different definitions of TRS, Wimberley et al (2016) reported a prevalence of 11%, 13% and 44% of patients with schizophrenia to be considered as having TRS \[[@pone.0234121.ref021]\], whereas 17% was reported in another study by the same author \[[@pone.0234121.ref022]\]. In UK, Demjaha et al (2017) reported that among a small cohort of people suffering from first episode schizophrenia, 23% were reported as treatment-resistant \[[@pone.0234121.ref023]\].

This discrepancy, both in the definition and prevalence of TRS in the literature makes it difficult to estimate the burden of TRS, which has important implications for decision makers in health policy and providers. An important reason for the lack of consistency in prevalence estimates is the difficulty and expense of conducting large scale epidemiological studies in this subgroup of patients with schizophrenia. One way to address this is to construct a mathematical model to simulate the temporal changes in the population of patients at risk of TRS using published epidemiological data together with national health statistics. The aim of the present study was to estimate the prevalence of TRS in the United States using a modelling approach.

Methods {#sec006}
=======

An Incidence-Prevalence-Mortality (IPM) model was used to estimate the prevalence of TRS in the United States. An IPM-model allows the investigator to estimate incidence, prevalence or mortality once two of the terms are known \[[@pone.0234121.ref024], [@pone.0234121.ref025]\]. A Markov Model assumes that an individual is always in one of several specified health states, with probabilities of transitions between the states during each cycle \[[@pone.0234121.ref026]\]. A one-year cycle was used for the following states in the study; Population, Schizophrenia, TRS and Dead. The population state are individuals in the cohort alive without a schizophrenia or TRS condition.

[Fig 1](#pone.0234121.g001){ref-type="fig"} presents the health states in the present study.

![Health states in the incidence-prevalence-mortality model.](pone.0234121.g001){#pone.0234121.g001}

Data {#sec007}
----

Baseline incidence rates of schizophrenia were taken from a systematic literature review by McGrath et al (2008) \[[@pone.0234121.ref027]\]. Evidence suggest different incidence rates of schizophrenia based on age and sex \[[@pone.0234121.ref028]\]. The population under 15 years of age and above 70 years of age was not considered to be at risk of incident schizophrenia. Considering the age and sex differences in the incidence of schizophrenia, the model input was therefore weighted with the baseline incidence rates to reflect these differences.

The incidence of TRS among patients with schizophrenia was taken from Wimberley et al 2016 \[[@pone.0234121.ref021]\]. They estimated the TRS incidence rate with three different proxy definitions:

1.  Clozapine initiation

2.  Clozapine initiation or eligible for clozapine (main definition)

3.  Clozapine initiation, eligible for clozapine or 90 days' polypharmacy.

This study uses the second definition as the main definition to proxy TRS. To obtain age and sex adjusted incidence rates for TRS, the incidence was weighted to the distribution of US patients with similar proxy in the Truven Health Market Scan database for Medicaid patients \[[@pone.0234121.ref029]\]. The incidence rates for schizophrenia and TRS were defined as annual risk to fit the one-year cycle in the model \[[@pone.0234121.ref030]\].

The mortality risk of individuals with schizophrenia were based upon those found by McGrath et al and operationalized as standardized mortality rates (SMR) \[[@pone.0234121.ref027]\]. A recent review found continuous clozapine use to be associated with 44% lower mortality rates compared to patients continuously exposed to another antipsychotics \[[@pone.0234121.ref031]\]. The SMRs for TRS mortality was therefore proportionally adjusted when proxy 1 was used. The mortality risk was assumed to be similar between schizophrenia and TRS patients when proxy 2 and 3 were used. As additional analyses, the SMRs for TRS in proxy 2 were similarly adjusted.

National statistics life tables provided by the U.S Social Security Administration was used as input to the age, gender and cohort specific mortality risks \[[@pone.0234121.ref032]\]. US Population data for 2014 was applied from U.S. Census Bureau \[[@pone.0234121.ref033]\].

R version 3.6.3 was used to model TRS and R Shiny to create an application that will allow the user to generate the prevalence of TRS in the United States for different input parameters. The R-code and data used in the study are available online ([S1 File](#pone.0234121.s001){ref-type="supplementary-material"}).

Statistical analysis {#sec008}
--------------------

Applying the Markov Model assumptions with the incidence and mortality risks for each birth cohort between 1930--2014, the individual birth cohort was then modeled to 2014 for each of the four states: Population, Schizophrenia, TRS and Dead. Prevalence of TRS was calculated as the cross-section of all cohorts in 2014, as being in the TRS state and converted to prevalence per 10,000 in the US population.

The analysis was performed using the median incidence rate of schizophrenia and the median SMRs among schizophrenia patients reported in McGrath et al (2008) \[[@pone.0234121.ref027]\]. Furthermore, a one-way sensitivity analysis was performed for the schizophrenia incidence input and the SMR rate inputs, where the reported 10^th^ and 90^th^ percentile of respectively incidence and SMRs was used. In addition, the model assumed no remission from the state of TRS to Schizophrenia, and no remission between the Schizophrenia state and population state.

Results {#sec009}
=======

The prevalence estimates of the different TRS definitions, along with selected incidence rate of schizophrenia and SMRs are presented in [Table 1](#pone.0234121.t001){ref-type="table"}. For each TRS definition, when the input parameters were changed, the estimated prevalence of TRS did, as expected, increase or decrease depending on scenario.

10.1371/journal.pone.0234121.t001

###### TRS prevalence results estimated using the IPM-model for USA 2014.

![](pone.0234121.t001){#pone.0234121.t001g}

  Input Parameters                                      Proxy 1                                               Proxy 2                                                Proxy 3                                                                                                                                                                                                                                                                       
  ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------- ------------------------------------ --------------------------------------- ------------------------------------
  IR SZ[^1^](#t001fn004){ref-type="table-fn"} (M / F)   RR SZ[^2^](#t001fn005){ref-type="table-fn"} (M / F)   RR TRS[^3^](#t001fn006){ref-type="table-fn"} (M / F)   Prevalence per 10,000[^4^](#t001fn007){ref-type="table-fn"} (M / F / Total)   TRS proportion (%)[^5^](#t001fn008){ref-type="table-fn"} (M / F / Total)   Prevalence per 10,000 (M / F / Total)   TRS proportion (%) (M / F / Total)   Prevalence per 10,000 (M / F / Total)   TRS proportion (%) (M / F / Total)
  **Median Incidence & Relative Risk**                                                                                                                                                                                                                                                                                                                                                                                                             
  1.5 / 1.0                                             2.8 / 2.5                                             1.8 / 1.7                                              6.4 / 2.8 / 4.6                                                               15.3 / 13.9 / 14.8                                                         9.0 / 4.1 / 6.5                         22.0 / 20.7 / 21.5                   19.7 / 9.1 / 14.3                       48.0 / 45.6 / 47.2
  **Incidence Rate Sensitivity**                                                                                                                                                                                                                                                                                                                                                                                                                   
  0.7 / 0.3                                             2.8 / 2.5                                             1.8 / 1.7                                              3.0 / 0.8 / 1.9                                                               15.3 / 13.9 / 15.0                                                         4.2 / 1.2 / 2.7                         22.0 / 20.6 / 21.6                   9.2 / 2.7 / 5.9                         48.0 / 45.6 / 47.4
  3.4 / 3.0                                             2.8 / 2.5                                             1.8 / 1.7                                              14.5 / 8.4 / 11.4                                                             15.3 / 13.9 / 14.8                                                         20.4 / 12.3 / 16.3                      22.0 / 20.7 / 21.5                   44.5 / 27.2 / 35.8                      48.1 / 45.7 / 47.1
  **Relative Risk Sensitivity**                                                                                                                                                                                                                                                                                                                                                                                                                    
  1.5 / 1.0                                             1.7 / 1.5                                             1.1 / 1.0                                              7.4 / 3.1 / 5.2                                                               15.7 / 14.1 / 15.2                                                         10.6 / 4.6 / 7.6                        23.0 / 21.3 / 22.5                   23.1 / 10.2 / 16.6                      49.9 / 46.8 / 48.9
  1.5 / 1.0                                             4.7 / 5.4                                             3.1 / 3.6                                              5.2 / 2.2 / 3.7                                                               14.5 / 13.3 / 14.1                                                         7.2 / 3.2 / 5.2                         20.5 / 19.2 / 20.1                   16.0 / 7.1 / 11.5                       45.5 / 43.0 / 44.7

Proxy 1 = Clozapine initiation

Proxy 2 = Clozapine initiation or eligible for clozapine. This is the main definition.

Proxy 3 = Clozapine initiation, eligible for clozapine or 90 days' polypharmacy

^1^ Median Incidence Rate of schizophrenia per 10,000 for males and females. The 10^th^ and 90^th^ percentile incidence rate is used for sensitivity \[[@pone.0234121.ref027]\].

^2^ Median Relative Risk of mortality in Schizophrenia state for males and females. The 10^th^ and 90^th^ percentile risk is used for sensitivity \[[@pone.0234121.ref027]\].

^3^ Relative Risk of morality in TRS state for males and females (only used for Proxy 1). The TRS state in proxy 2 and 3 uses the same relative risk as the Schizophrenia state.

^4^ Prevalence of Treatment-Resistant Schizophrenia per 10,000 for males, females and total.

^5^ Proportion (%) of Treatment-Resistant Schizophrenia patients among people suffering from schizophrenia.

The second proxy, which was the main scenario, together with the median incidence rate and SMRs, resulted in an estimated prevalence of TRS of 6.5 per 10,000 and a proportion of TRS of 21.5% among the schizophrenia population in the US in 2014. Comparing the one-way sensitivity analysis when changing the SMR rates while keeping the incidence rates constant, the model estimated a prevalence of TRS when using the 10^th^ percentile of the SMR rate to be 7.6 per 10,000 as compared to 5.2 per 10,000 when the 90^th^ percentile was used. Likewise, for the one-way sensitivity analysis of incidence rate of schizophrenia, the estimated prevalence of TRS increased from 2.7 to 16.3 per 10,000 when comparing the 10^th^ percentile of incidence rate to the 90^th^ percentile. Regardless of parameter input, the proportion of TRS did not change within the three different proxies.

Assuming the SMRs for schizophrenia and TRS would be different in proxy 2, as it is assumed in proxy 1, would result in a prevalence of 7.3 per 10,000 using the main definition. In contrast, if the SMR for TRS was increased by 25% relative to schizophrenia in proxy 2, it would yield a prevalence of 6.1 per 10,000.

The model found substantial impact on the estimated prevalence and the proportion of schizophrenia with TRS depending on proxy definition. The prevalence estimates ranged between 4.6 per 10,000 for the first and 14.3 per 10,000 for the third proxy. The proportion of TRS patients among patients with a schizophrenia condition ranged between 14.8 for the first proxy and 47.2 for the third proxy.

Discussion {#sec010}
==========

An IPM-model was applied to model the prevalence and proportion of TRS patients among the schizophrenia population in the US. The three proxy definitions of TRS yielded substantial differences in the estimated prevalence and proportions of TRS. Furthermore, the one-way sensitivity analysis revealed the large impact on prevalence of changing incidence and mortality risks. The model estimated the proportion of TRS patients in the schizophrenia population to be in the range of 21--22% for the main scenario by applying incidence rates and SMR rates from McGrath et al (2008) \[[@pone.0234121.ref027]\]. This result is similar to Demjaha et al (2017) who reported 23% to be treatment-resistant among a small UK cohort of people suffering from first episode schizophrenia \[[@pone.0234121.ref023]\]. The model used the same proxies for TRS as a Danish study which reported the proportion of TRS to be 11%, 13% and 44% among schizophrenia patients \[[@pone.0234121.ref021]\]. For each of the proxies, the model developed in this study report similar, albeit consistently higher estimates of TRS in the United States for 2014.

Despite the one-way sensitivity analyses revealing large variations in the prevalence estimates, all estimates for the different combination of proxies and parameter inputs are well within the range reported by Dammak et al 2013, who reported the proportion of TRS to be in the range of 5--60% \[[@pone.0234121.ref019]\]. The large differences reported in Dammak et al 2013 can mainly be attributed different definitions of TRS. The results in this study suggests that the proportion of TRS patients is driven by the definition of TRS, whereas changing risk of mortality only shows minor impact. The prevalence of TRS per 10,000 was very sensitive to changes in the incidence rate of schizophrenia, which in the main definition of TRS, changed the prevalence from 2.7 to 16.3 per 10,000 when changing the incidence rate of schizophrenia from 0.7 to 3.4 per 10,000.

The incidence rates used in this study were derived from a systematic review published in 2008 that summarized 158 studies of schizophrenia incidence \[[@pone.0234121.ref027]\]. By applying the 10^th^ and 90^th^ percentiles of the incidence rates reported in literature, plausible ranges were derived under the different assumptions. A review and meta-analysis performed on UK studies reported a pooled incidence of schizophrenia of 15.2 per 100,000 person-years \[[@pone.0234121.ref034]\], which is almost identical to the median incidence rate reported in McGrath et al 2008 \[[@pone.0234121.ref027]\]. Recently Castillejos et al (2018) reported a pooled incidence rate of 22.5 and 7.2 per 100,000 for non-affective and affective psychosis respectively \[[@pone.0234121.ref035]\]. The plausible ranges coincide well with the estimated ranges by the model in this study.

The applied SMRs in the model were derived from a systematic review containing 37 studies on mortality \[[@pone.0234121.ref027]\]. A recent study from the US by Olfson el at (2015) \[[@pone.0234121.ref036]\], reported a relative risk of mortality of 3.7 from schizophrenia compared to the general population. The relative risk reported by Olfson et al (2015) is between the median and high SMR scenario in the one-way analyses, and the results in this study may thus be considered robust to changes in the SMR.

Proxy 1 assumed a lower SMR for TRS than the schizophrenia state. This assumption was also tested for the main definition proxy 2, showing a slightly lower prevalence compared to the prevalence without this assumption. Assuming a lower SMR for TRS compared schizophrenia in proxy 2 would require supportive evidence, and to the best of the authors knowledge, this does not exist.

An IPM simulation approach takes cohort time-varying mortality into account, and given reasonable inputs, it allows to test the implications of different TRS definitions and its prevalence. Informed estimates of the burden of TRS on individuals and society remains a challenging task. The results may help policymakers identify a large and tangible patient population with need for adequate treatment, and in the future avoid under -or over estimations of the societal burden of TRS.

Further research could be done to incorporate a probabilistic sensitivity analysis to the IPM model, by running the model with e.g. 10,000 draws from distributions of each input parameter, to provide a more advanced exploration of uncertainty from the inputs in the IPM model.

Limitations {#sec011}
-----------

The model assumed the incidences rates and relative risks of mortality to be constant over time, despite evidence suggesting these parameters to evolve over time. Increasing incidence rates for schizophrenia was reported for those aged below 33, whereas decreasing incidence rates were reported for those aged 33 and above over the period 2000--2012 in Denmark. When analyzed together, an increase of approximately 20% was reported \[[@pone.0234121.ref037]\]. Changing relative risks were reported in Saha et al \[[@pone.0234121.ref038]\]. In addition, divergent trends in longevity have been reported; increasing longevity for the general population and decreasing longevity for the schizophrenia population \[[@pone.0234121.ref039]\].

The incidence rate of TRS is applied from a Danish cohort study by Wimberley et al. \[[@pone.0234121.ref021]\], hence the analysis is a synthesis of US and non-US sources to estimate the TRS prevalence in the US. If the incidence rates of TRS differs significantly between Denmark and the US, given the same proxy was applied, it would introduce bias to the estimate due to lack of exchangeability coming from demographic, biological composition or clinical differences. However, the clozapine use between Denmark and the US was found to be close on average, with differences depending on whether the US patients are privately or publicly insured \[[@pone.0234121.ref040]\]. This supports the validity of proxy one, but it was not possible to validate the main proxy.

The analysis used three different proxies of TRS, all suggested in the same article by Wimberley et al 2016 \[[@pone.0234121.ref021]\]. The analysis may thus have omitted other definitions of TRS available in the literature. In the present study, the main driver of the prevalence of TRS was the proxy used to define TRS, thus an additional definition would be expected to impact the estimate of TRS. To the best of the authors knowledge, there are no external data sources available allowing for external validation of our predicted TRS prevalence estimates in a representative sample.

The model used in the present study did not allow remission from the state of TRS to schizophrenia, or remission between the schizophrenia state and population state. The Remission in Schizophrenia Working Group defined consensus-based operational criteria for symptomatic remission among patients with schizophrenia \[[@pone.0234121.ref041]\]. However, as with the definition of TRS, there is a lack of consensus on the definition of functional remission \[[@pone.0234121.ref042]\]. A recent review of remission rates in schizophrenia reported rates between 17% to 78% for first-episode schizophrenia and between 16% to 62% in multiple-episode patients \[[@pone.0234121.ref043]\]. Despite this, it would be of interest if future IPM-models could incorporate remission.

The data used in the present study, national statistics life tables and population data, were provided by official population registers, thus the accuracy and reliability should be high.

Furthermore, the model used in the present study does not explicitly consider other factors known to impact the incidence of schizophrenia, such as ethnicity \[[@pone.0234121.ref044]\], migrant status \[[@pone.0234121.ref045], [@pone.0234121.ref046]\] and use of cannabis \[[@pone.0234121.ref047], [@pone.0234121.ref048]\]. Increased granularity in the input parameters of the model with regards to, for instance, differences in incidence and longevity between different ethnic groups would provide improved estimates.

Conclusion {#sec012}
==========

The study estimated that approximately 22% of the schizophrenia patients had TRS in the United States for the main scenario. The estimates are highly dependent on the proxy used and as no uniform definition of TRS is available, estimating the burden of TRS on individuals and society remains a challenging task.

Supporting information {#sec013}
======================
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In general the paper is well-written and many PLOSONE readers should find it relatively easy to read and without a great deal of technical jargon. One exception involves a number of instances in which the subject of the sentence is a singular or a plural noun and the other parts of the sentence (e.g., verb form; subject complement) are the opposite. This situation can be remedied with some careful copyediting.

Reviewer \#2: This study performs a Markov cohort simulation to model prevalence of treatment resistant schizophrenia. It uses data from public health databases as well as estimates from published estimates from systematic reviews.

Overall the study is interesting and contributes to the literature. The methods are appropriate to address the question, and it is written clearly and is readable for non-specialists. However, the report is also very brief and includes only one analysis using previously published data. Some recommendations are:

1\) Various typos or other problems that should be corrected:

a\. In the first paragraph of the introduction, line 5: 'Some patients diagnosed with schizophrenia do only...' Remove 'do'.

b\. Last sentence of the first paragraph of the introduction: 'Additionally, half of the patients with TRS is...' Remove 'the' and change 'is' to 'are'.

c\. Last sentence of the introduction: 'United Stated'.

d\. In the last paragraph of the Data section of the Methods (p.4, line 21): 'TRS mortality was therefore adjusted proportionally adjusted...' Repeated use of the word 'adjusted'.

e\. In the second paragraph of the Statistical Analysis section of the Methods (p.4, line 32): 'The analysis were performed...' Change 'were' to 'was'.

f\. The second sentence of the Discussion ('The three different proxy definitions of TRS...') is confusing. It would be helpful to reword it.

g\. The last sentence of the first paragraph of the Discussion ('albeit consistently higher estimates of TRS...'): United States is not capitalised properly.

h\. First sentence of the second paragraph of the Discussion ('Despite the one-way sensitivity analyses'): the sentence is confusing. Perhaps 'revealed' should be changed to 'revealing'.

i\. The last sentence of the third paragraph of the Discussion ('the plausible ranges well coincide') is clumsily worded. Perhaps 'the plausible ranges coincide well'?

j\. The last sentence of the Conclusion ('The estimates are highly dependent of...') is confusing. Perhaps '...are highly dependent on the proxy used...'?

2\) If feasible to do so, it would be useful for the reader to include descriptives/summary statistics in the Results section about the data used for the analyses, although I am conscious that a number of data sets were used and that they were previously published elsewhere. At the moment it is unclear what the characteristics of the sample(s) used to estimate TMR prevalence were or how representative they were of the wider population.

3\) In the Methods section, there are multiple assumptions described that were made for the model. For example, it is stated that the SMRs for TRS mortality was adjusted proportionally for proxy 1, but not for proxy 2 or 3. While I think that the rationale for these assumptions is reasonable, it would be helpful to add a discussion of these assumptions and how they may have impacted the results of the analysis to the limitations section in the Discussion.

Reviewer \#3: I can congratulate the authors on their conceptualization of an interesting schizophrenia research question \-- namely, how often treatment-resistant schizophrenia might be occurring in the United States. They appropriately identify a crucial issue- namely, how TRS case definitions are actualized.

The data they have pulled together seems quite appropriate, but it is possible that they have neglected some sources of data that are pertinent, and this topic deserves coverage in a revised limitations section of the paper.

Of special note might be the continuing uncertainty about whether any of the US databases now encompass the entire study population of cases of schizophrenia, within which the treatment-resistant case subset might be found.

Leaving aside issues of the completeness of the data and coverage of the US schizophrenia population, there are some uncertainties about the statistical modeling approach. Taking a step backward one might look for simulations that are more advanced (e.g., with Gibbs sampling), and here again, it is a topic for coverage in the Discussion section but not necessarily a serious impediment in relation to publication of this paper\'s estimates.

I remain unconvinced that the 22% estimate offered by the authors is that much different from the 30% estimate in the literature of the past. In addition, the description of the statistical approach does not mention how the 30% estimate might be used as a Bayesian prior, with the new evidence used to update that prior.

I\'d be especially appreciative of a statistical approach that takes the 30% estimate as a Bayesian prior, and then evaluates that prior in relation to the new data now available.

Finally, I\'d invite the authors to talk more about external generalizability, and here there is an important literature that might not be fully appreciated by PLOS readers and that stretches back to the US-UK diagnostic studies and the Sartorius-Wing group\'s work on the IPSS schizophrenia research. Some 38 citations are included, but I\'m not seeing the important seminal work completed in that clearly pertinent study with samples from multiple countries.

Reviewer \#4: This is an interesting paper based on simulations underpinned by epidemiological data to inform IPM models about the prevalence of TRS. The incidence data come from reliable sources, and the methodology appears sound, notwithstanding the points below which can mostly be easily addressed. I have a concern about the birth cohorts that were used for this exercise, and no method of validation of the model is reported in the methods, another major limitation.

1\. Introduction: It's unclear which reference the "30%" quote comes from. Is this based on a meta-analysis or similar?

2\. Methods: Did you IPM model allow for the possibility of symptomatic or disease recovery / remission? If not, how could this have influenced your estimates?

3\. Methods\>Data: The model is restricted by other covariates over which incidence of schizophrenia varies, but which are not explicitly modelled. These would include ethnicity/migration status and cannabis use. Could the authors comment on how omitting these (and other) omitted variables could have affected TRS prevalence estimates?

4\. Methods\>Statistical Analysis: Please give more information about where you obtained the birth cohort data (1930-2014) from and how this was set up (i.e. stratified by sex?). How long were people simulated as at-risk of schizophrenia for? Typically this would be from \~16-64 years of age. I don't understand the analysis fully here as you report the TRC prevalence for 2014. On this basis birth cohorts from 1998 onwards would not be relevant to your study, since they would be younger than 16 in 2014. The earliest lower age of onset I think you could go down to is 14 years, but 16 is more typical. This should be clarified. Equally, birth cohorts born in 1930 would be aged 84 in 2014, well passed the typical age of onset of psychosis. Very late onset psychosis has a distinct epidemiology, about which little is known with respect to TRS.

5\. Methods\>Statistical Analysis: How was the simulation model validated?

6\. Table 1: Should there be corresponding confidence intervals around the prevalence of TRS and TRC proportion amongst people with schizophrenia?

7\. Results: The text is unclear in places, for example "Comparing the one-way sensitivity analysis when changing the SMR rates...the model estimated an approximately 40% higher prevalence..." -- it's unclear to which line in Table 1 you are referring. Preference would be to report the TRS proportions specified in the Table, not the % change in TRS proportions. Similar argument for the "fivefold" increase.

Minor points:

8\. Please remember to include page numbers which makes reviewing easier

9\. Introduction: "...half of the patients with TRS is..." should be "...TRS are..."

10\. Define acronyms on first usage, ICD, DSM etc

11\. Table 1: You could indicate in the table, that Proxy 2 was the main definition to remind the reader at this point.

12\. Discussion: Second sentence is unclear

13\. Why did the authors chose the US population?

14\. I did not have access to the full data in supplemental files, which were not provided to me. The authors may wish to check with PLoS One that open access to this data is available.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: James C. Anthony

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: Yes: James B. Kirkbride Ph.D.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234121.r002

Author response to Decision Letter 0

6 Apr 2020

Author response to reviewers' comments:

Reviewer \#1: I was unable to find the \'Supporting Information\' files that the authors promised to provide, unless the intent was to consider the manuscript text itself as a \'Supporting Information\' file

In addition, the authors did not provide the spreadsheet or other software used to implement the Markov model.

These omissions actually make it difficult to make a full evaluation of this contribution, and some details required to confirm rigor and reproducibility of the estimates are missing.

Author response: Thanks for pointing this out to us. We think it is important that all data as well as the R-code used is available to the reviewers, and to the reader. In the resubmission we have provided the life tables for the life expectancy in the United States and the R code used in the IPM-model. In addition, we have made a Shiny-application in R, making it easy for the reader to change the proxies, SMRs etc, and see the resulting modelled prevalence of TRS in the United States.

As for the SMRs, they come from published literature which we have cited.

That being said, if we make an assumption that the authors have acted and performed the research task with integrity and in a fashion that is acceptable from the standpoint of rigor and reproducibility, it should be noted that this contribution has a focus on the construct of \'Treatment-Resistant Schizophrenia,\' often conceptualized as a categorical phenomenon or as one end of a spectrum of treatment responsiveness, and the size of the TRS caseload is of interest in pharmacoeconomics and pharmacoepidemiology as might be seen when pharmaceutical industry research and development decisions are made about investments in new medications for schizophrenia. Further, the results of the Markov modeling appear to be sound and logic supports descriptive statements provided by the authors, who offer several simulations, each based on reasonably plausible assumptions (e.g., concerning SMR to the extent that excess mortality might be shortening the lives of people who suffer from treatment-resistant schizophrenia. Further, there is a clearly stated set of limitations and assumptions, which should be helpful as a guide to future modeling work along these lines. It is of interest that the authors adopted a deterministic approach and did not use simulation approaches that might provide interval estimates to complement the point estimates. (One might say that the three \'proxy\' approaches lay out a set of alternative estimates that might be used in place of credible intervals or confidence intervals.)

Author response: We thank the reviewer for the thoughtful comments, which we believe have improved the manuscript.

A few minor comments:

The authors mention \'true prevalence\' and this echoes some prior literature in the field, but indeed what we have are estimates and it might be argued that the construct of \'true prevalence\' should have been abandoned long ago. The authors provide reasons for rejecting this notion, and they offer a range of estimates, each based on plausible assumptions about deterministic values in the Markov modeling simulations.

Author response: This is a valid point. In the revised version we do not refer to the true burden or true prevalence of TRS.

In general the paper is well-written and many PLOSONE readers should find it relatively easy to read and without a great deal of technical jargon. One exception involves a number of instances in which the subject of the sentence is a singular or a plural noun and the other parts of the sentence (e.g., verb form; subject complement) are the opposite. This situation can be remedied with some careful copyediting.

Author response: We have had the manuscript thoroughly checked for such occasions.

Reviewer \#2: This study performs a Markov cohort simulation to model prevalence of treatment resistant schizophrenia. It uses data from public health databases as well as estimates from published estimates from systematic reviews.

Overall the study is interesting and contributes to the literature. The methods are appropriate to address the question, and it is written clearly and is readable for non-specialists. However, the report is also very brief and includes only one analysis using previously published data. Some recommendations are:

Author response: We would like to thank the reviewer for the good comments and suggestions, which we believe have helped improve the manuscript

1\) Various typos or other problems that should be corrected:

a\. In the first paragraph of the introduction, line 5: 'Some patients diagnosed with schizophrenia do only...' Remove 'do'.

b\. Last sentence of the first paragraph of the introduction: 'Additionally, half of the patients with TRS is...' Remove 'the' and change 'is' to 'are'.

c\. Last sentence of the introduction: 'United Stated'.

d\. In the last paragraph of the Data section of the Methods (p.4, line 21): 'TRS mortality was therefore adjusted proportionally adjusted...' Repeated use of the word 'adjusted'.

e\. In the second paragraph of the Statistical Analysis section of the Methods (p.4, line 32): 'The analysis were performed...' Change 'were' to 'was'.

f\. The second sentence of the Discussion ('The three different proxy definitions of TRS...') is confusing. It would be helpful to reword it.

g\. The last sentence of the first paragraph of the Discussion ('albeit consistently higher estimates of TRS...'): United States is not capitalised properly.

h\. First sentence of the second paragraph of the Discussion ('Despite the one-way sensitivity analyses'): the sentence is confusing. Perhaps 'revealed' should be changed to 'revealing'.

i\. The last sentence of the third paragraph of the Discussion ('the plausible ranges well coincide') is clumsily worded. Perhaps 'the plausible ranges coincide well'?

j\. The last sentence of the Conclusion ('The estimates are highly dependent of...') is confusing. Perhaps '...are highly dependent on the proxy used...'?

Author response: Thank you for these comments. All the comments above have been implemented in the revised version of the manuscript.

2\) If feasible to do so, it would be useful for the reader to include descriptives/summary statistics in the Results section about the data used for the analyses, although I am conscious that a number of data sets were used and that they were previously published elsewhere. At the moment it is unclear what the characteristics of the sample(s) used to estimate TMR prevalence were or how representative they were of the wider population.

Author response: Thanks for pointing this out to us. As we wrote in the answer to reviewer 1, we think it is important that all data as well as the R-code used is available to the reviewers, and to the reader.

We have provided the life tables for the life expectancy in the United States and the R code used in the IPM-model. In addition, we have made a Shiny-application in R, making it easy for the reader to change the proxies, SMRs etc, and see the resulting modelled prevalence of TRS in the United States.

As for the SMRs, they come from published literature which we have cited.

3\) In the Methods section, there are multiple assumptions described that were made for the model. For example, it is stated that the SMRs for TRS mortality was adjusted proportionally for proxy 1, but not for proxy 2 or 3. While I think that the rationale for these assumptions is reasonable, it would be helpful to add a discussion of these assumptions and how they may have impacted the results of the analysis to the limitations section in the Discussion.

Author response: This is a good suggestion. As additional analyses we adjusted the mortality risks for the other proxies downwards in a similar fashion to investigate the impact that would have to the results. This was also added in the discussion section.

Reviewer \#3: I can congratulate the authors on their conceptualization of an interesting schizophrenia research question \-- namely, how often treatment-resistant schizophrenia might be occurring in the United States. They appropriately identify a crucial issue- namely, how TRS case definitions are actualized.

The data they have pulled together seems quite appropriate, but it is possible that they have neglected some sources of data that are pertinent, and this topic deserves coverage in a revised limitations section of the paper.

Author response: We would like to thank the reviewer for the suggestions and comments on our work. These helped improve the paper. As suggested, we have added the impact of possibly omitting some sources in the limitations section.

Of special note might be the continuing uncertainty about whether any of the US databases now encompass the entire study population of cases of schizophrenia, within which the treatment-resistant case subset might be found.

Author response: We unfortunately don't have access to such US database with a complete schizophrenic population. Applying the same proxies to estimate the prevalence of TRS in such a setting would be very interesting. Our approach, using the basic code which is now made available to the reader, should however be transferable to other countries or regions without the need to access a database. That is, by uploading region or country specific life tables the reader should be able to generate estimates of the TRS prevalence rapidly.

Leaving aside issues of the completeness of the data and coverage of the US schizophrenia population, there are some uncertainties about the statistical modeling approach. Taking a step backward one might look for simulations that are more advanced (e.g., with Gibbs sampling), and here again, it is a topic for coverage in the Discussion section but not necessarily a serious impediment in relation to publication of this paper\'s estimates.

Author response: We agree with the reviewer that it would be of interest to perform a more advanced simulation to obtain uncertainty around the estimates. E.g. sampling 10.000 times from the distribution in a frequentist manner or using a Gibbs sampling approach in a bayesian framework. The current deterministic sensitivity analysis explores the one-way uncertainty in the estimate, and we like the simplicity of the model, which makes it easy for the reader to understand the model and how changes in the parameters impact the prevalence.

I remain unconvinced that the 22% estimate offered by the authors is that much different from the 30% estimate in the literature of the past. In addition, the description of the statistical approach does not mention how the 30% estimate might be used as a Bayesian prior, with the new evidence used to update that prior. I\'d be especially appreciative of a statistical approach that takes the 30% estimate as a Bayesian prior, and then evaluates that prior in relation to the new data now available.

Author response: We agree with the reviewer that the difference is not that large, and we have worded this carefully where we state that "The results suggests that prevalence of TRS may be somewhat lower than the 30% often reported, however this is highly dependent on the definition of treatment resistance"

Finally, I\'d invite the authors to talk more about external generalizability, and here there is an important literature that might not be fully appreciated by PLOS readers and that stretches back to the US-UK diagnostic studies and the Sartorius-Wing group\'s work on the IPSS schizophrenia research. Some 38 citations are included, but I\'m not seeing the important seminal work completed in that clearly pertinent study with samples from multiple countries.

Author response: We would like to thank the reviewer for pointing out this literature. To the external generalizability, an extension to the limitations section have been added to accommodate this.

Reviewer \#4: This is an interesting paper based on simulations underpinned by epidemiological data to inform IPM models about the prevalence of TRS. The incidence data come from reliable sources, and the methodology appears sound, notwithstanding the points below which can mostly be easily addressed. I have a concern about the birth cohorts that were used for this exercise, and no method of validation of the model is reported in the methods, another major limitation.

Author response: Thank you for your constructive comments on our paper.

1\. Introduction: It's unclear which reference the "30%" quote comes from. Is this based on a meta-analysis or similar?

Author response: We have added references in the revised version of the paper.

2\. Methods: Did you IPM model allow for the possibility of symptomatic or disease recovery / remission? If not, how could this have influenced your estimates?

Author response: This is an important point and we state in the method section that the model did not consider the possibility of disease recovery. We have added a discussion on this in the limitation section.

3\. Methods\>Data: The model is restricted by other covariates over which incidence of schizophrenia varies, but which are not explicitly modelled. These would include ethnicity/migration status and cannabis use. Could the authors comment on how omitting these (and other) omitted variables could have affected TRS prevalence estimates?

Author response: This is a good suggestion. We have added a paragraph on this in the limitation section.

4\. Methods\>Statistical Analysis: Please give more information about where you obtained the birth cohort data (1930-2014) from and how this was set up (i.e. stratified by sex?). How long were people simulated as at-risk of schizophrenia for? Typically this would be from \~16-64 years of age. I don't understand the analysis fully here as you report the TRC prevalence for 2014. On this basis birth cohorts from 1998 onwards would not be relevant to your study, since they would be younger than 16 in 2014. The earliest lower age of onset I think you could go down to is 14 years, but 16 is more typical. This should be clarified. Equally, birth cohorts born in 1930 would be aged 84 in 2014, well passed the typical age of onset of psychosis. Very late onset psychosis has a distinct epidemiology, about which little is known with respect to TRS.

Author response: Good point. We set the transition probabilities for the population under 15 years of age or above 70 years of age between the population and schizophrenia state to be 0. Therefore, it was not possible for those age groups to become schizophrenics. We have added this explanation in the revised version of the manuscript.

National statistics life tables were provided by the U.S Social Security Administration and can be found in the supplementary material.

5\. Methods\>Statistical Analysis: How was the simulation model validated?

Author response: This is an important point. We internally validated the model and its methodological framework among clinical and statistical experts in Lundbeck to an extend where our experts believed it was both clinical and statistical sound, however, this is not discussed in the article. Additionally, we discuss confounding and generalizability of the model and its framework in the discussion and limitations section.

6\. Table 1: Should there be corresponding confidence intervals around the prevalence of TRS and TRC proportion amongst people with schizophrenia?

Author response: We think that the intervals provided in the table are highlighting the uncertainties in the estimates.

7\. Results: The text is unclear in places, for example "Comparing the one-way sensitivity analysis when changing the SMR rates...the model estimated an approximately 40% higher prevalence..." -- it's unclear to which line in Table 1 you are referring. Preference would be to report the TRS proportions specified in the Table, not the % change in TRS proportions. Similar argument for the "fivefold" increase.

Author response: We have changed this according to the reviewer's suggestion.

Minor points:

8\. Please remember to include page numbers which makes reviewing easier

Author response: We have added this.

9\. Introduction: "...half of the patients with TRS is..." should be "...TRS are..."

Author response: Changed

10\. Define acronyms on first usage, ICD, DSM etc

Author response: Thanks for pointing this out to us. We have gone through the manuscript again and corrected all such occasions.

11\. Table 1: You could indicate in the table, that Proxy 2 was the main definition to remind the reader at this point.

Author response: Good suggestion, we added this in the table.

12\. Discussion: Second sentence is unclear

Author response:

13\. Why did the authors chose the US population?

Author response: We chose the US population because of the available public data for this population and due to the size of the patient population and its burden on society.

14\. I did not have access to the full data in supplemental files, which were not provided to me. The authors may wish to check with PLoS One that open access to this data is available.

Author response: Thanks for pointing this out to us. These should be available in the resubmission.

###### 

Submitted filename: renamed_a2543.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0234121.r003
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Dear Mr. Mørup,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 22 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppe Carrà, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Partly

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The authors have largely addressed the issues raised and the paper is improved for it. One final suggestion would be to add a limitation to the paper clearly acknowledging the potential issues with data accuracy and reliability in the datasets they have used.

Reviewer \#4: Thank you for addressing my concerns, which are generally clear and have helped to improve the manuscript. One concern that I feels requires further detail and revision is over validation. The abstract of the paper states that the model was validated for the purpose of estimate the prevalence of TRS in the US. The author response to my earlier concern with this issue, however, noted that validity had been established by asking clinicians and statistical experts about the model and its methodological framework. This is not really internal validity but some measure of apparent or face validity. Internal validity would be more formally established using bootstrapping or some other cross-validation procedure applied to the available data. There is also no mention of any external validation (do the predictions from your model accurately predict TRS prevalence in the US in a representative sample?), which may not be possible in the absence of a reliable external dataset in which to test this. If so, external validation can simply be acknowledged as a limitation, but I would think there is more the authors could do to internally validate their models.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

Reviewer \#4: Yes: James B. Kirkbride

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234121.r004

Author response to Decision Letter 1

18 May 2020

Author response to reviewers' comments:

Reviewer \#2: The authors have largely addressed the issues raised and the paper is improved for it. One final suggestion would be to add a limitation to the paper clearly acknowledging the potential issues with data accuracy and reliability in the datasets they have used.

Author response: We would like to thank the reviewer for the thoughtful comments on this and the previous version of the manuscript.

We added a paragraph in the limitation section focusing on potential issues with the data used to model TRS.

Reviewer \#4: Thank you for addressing my concerns, which are generally clear and have helped to improve the manuscript. One concern that I feels requires further detail and revision is over validation. The abstract of the paper states that the model was validated for the purpose of estimate the prevalence of TRS in the US. The author response to my earlier concern with this issue, however, noted that validity had been established by asking clinicians and statistical experts about the model and its methodological framework. This is not really internal validity but some measure of apparent or face validity. Internal validity would be more formally established using bootstrapping or some other cross-validation procedure applied to the available data. There is also no mention of any external validation (do the predictions from your model accurately predict TRS prevalence in the US in a representative sample?), which may not be possible in the absence of a reliable external dataset in which to test this. If so, external validation can simply be acknowledged as a limitation, but I would think there is more the authors could do to internally validate their models.

Author response: We thank the reviewer for these thoughtful comments and for helping us improve the quality of the paper.

The reviewer raises an important point about the validation of the model. We deleted the statement in the abstract regarding validation, as the model, as noted by the reviewer, has not been thoroughly validated. We did expand the limitation section to address issues concerning external validation.

We do however disagree with the reviewer that we can do more regarding internal validity. The reviewer suggested more could be done using on internally validating the model by use of bootstrapping or cross-validation. Such approaches are very useful when data allows sampling, however the data used in the present simulation does not allow for such sampling. The life tables used to derive the age, gender and cohort specific mortality risks does not have any variation in it, nor does the population data. Regarding the epidemiological inputs, the base scenario for each proxy were based on the medians from published literature and were presented along with the 10th and 90th percentiles, which produced a deterministic range for the results.
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